ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.
ESC 2020 A study including 48 RCTs demonstrated that lowering of each 5 mmHg SBP resulted in 10% reduction of major CV events, regardless of baseline SBP and CVD status.
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.
CSI Paris Eline Groenland asks Dan Lane about his novel screening method using urine samples that can detect whether hypertensive patients take their drugs. This test may help to improve medical adherence.
ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.
ESC 2019 A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.
Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.
Bryan Williams, co-chair of the 2018 ESC/ESH Hypertension Guidelines, lists the most important new recommendations. Furthermore, he comments on the discussion on differences between the European and American recommendations.
Neil Poulter stresses that, although high BP is considered a boring topic by some, it is crucial to be aware of it before it can be treated properly. You too can get involved in raising awareness.
ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.
ESC 2018 Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.
Clinical updates in management of cardiovascular risk Hypertension is one of the most established and major risk factors for CVD. Prof Hobbs gives an overview on the impact of hypertension on CV outcomes, how the diagnosis is made, on the benefits of therapy, and what the BP targets are.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
VBWG at ACC 2018 After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.
ACC 2018 Black barbershops and pharmacists worked together to improve high BP in non-hispanic black men. In a randomized design, a pharmacist intervention led to 27 mmHg drop in SBP over 6 months, vs. 9 mmHg in controls.
AHA 2017 Prof. Clyde Yancy summarizes the most important new recommendations, starting with a new definition of hypertension, the need for a risk conversation and implications for therapy.
AHA 2017 In the SPRINT study, BP was not always measured in absence of a physician or nurse. A posthoc survey investigated whether this affected the findings of the study.
AHA 2017Although the broad statements remain intact, the target in BP lowering differs between Europe and USA; prof Yancy explains why.
AHA 2017 A lot of variation in BP measurement methods was seen in SPRINT, despite the protocol, but in 3/4 of sites patients were alone at least at some point during the BP reading.
AHA 2017 Paul Whelton, chair of the 2017 Hypertension Practice Guidelines, summarises the major changes as compared with the previous guideline.
ESC 2017 Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.
ESC 2017 Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.
ESC 2017 The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.
ESC 2017 After seeing the PRECISION-ABPM results, Ruschitzka concludes that use of ibuprofen may need to be reconsidered in hypertensive arthritis, as its BP-increasing effect is stronger than that of celecoxib and naproxen.
ACC 2017 Dr. Rob Nolan presented the results of the REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.
Prof. Neil R Poulter, MD, ISH President, calls for participation in May Measurement Month (MMM17). MMM17 is a global Blood Pressure Awareness Campaign, incorporating World Hypertension Day.
Dr. Deepak L. Bhatt, MD, MPH, discusses the ongoing issue on how low to go with blood pressure - is there a J-curve or not? Lowering blood pressure too much may be associated with adverse CV outcomes, supporting the existence of a J-curve phenomenon.
CSI ROME Nicolette van der Sande and Monique van Kleef critically discuss the SPRINT trial results with William Cushman and Sverre Kjeldsen. The professors disagree on whether these results should influence new guidelines.
Dr. Per-Henrik Groop outlines that diabetic kidney disease is common and associated with a grim prognosis. Optimal glucose control is central to limiting the risk of renal complications. Newer antidiabetic drugs can play a welcome role to optimally treat these patients.
BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk
ACC 2016 Prof. Salim Yusuf discusses the results of the HOPE-3 study, which indicates that statins are effective in all patients with intermediate CVD risk, whereas blood pressure lowering is only effective in hypertensive patients.
ESC 2015 The PARAMETER study evaluated LCZ696, the agent that was found to be effective against heart failure in the PARADIGM-HF, in another population of patients with systolic hypertension. Prof. Bryan Williams discusses the results.
ESC 2015 The PARAMETER study evaluated LCZ696, the agent that was found to be effective against heart failure in the PARADIGM-HF, in another population of patients with systolic hypertension.
ESC 2015 Prof. Bryan Williams (Londen) presented the PATHWAY-2, in which 3 different additional agentsto treat therapy resistant hypertension were compared. Spironalactone clearly performed better than the other two.
Prof John McMurray, Glasgow, explains the backgrounds of this trial with a novel ARNI and its potental implications for future Heart Failure management
Prof. Susekov, Moscow, with a brief update on current challenges to manage CVD in Russia, including some take home messages for Russian physicians
Prof. Bryan Williams (London) urges the need for innovation to control systolic BP in our aging population
Lecture held by Prof Bryan Williams, MD, UCL, London, United Kingdom on 'Innovating hypertension management beyond current therapies: What are the opportunities?' held during the PACE 2014 Snapshot session in Barcelona
Dr. Peter Meredith, Glasgow, UK, expresses his concerns about the potential impact of new hypertension guidelines on patients at increased CV risk and emphasises the importance of tight sustained blood pressure control.
Dr. Ruilope provides guidance for better measurement of blood pressure, for better management of this risk factor.
Prof. John E Deanfield highlights the key messages of JBS3: a new approach to CVD prevention, considering 'lifetime CV risk' and 'heart age'.
As presented by prof Luis Ruilope, during the PACE 2013 SNAPSHOT session on August 31, 2013 in Amsterdam
Prof. Luis Ruilope about current options to manage therapy resistant hypertension.
Prof. Peter Sever, London, argues if all drug classes have the same effect, if blood pressure should be targeted aggressively, and if BP variability is important.
Dr. Domenic Sica (Virginia) reviews new developments in drug therapy and a range of new devices targeting the unmet need for controlling hypertension
Prof Michael Weber provides his expectations on the right level of blood pressure targets, the elderly patients and optimal therapies
Domenic Sica (Richmond, USA) provides an overview of new drugs and therapies in development for hypertension (aldosterone antagonists, renal denervation).
Dr Horst Sievert, Germany, highlights current status of catheter based techniques to treat resistant hypertension.
Prof. Ruilope, Hopital 12 de Octubre, Madrid, Spain discusses recommendations in the management of hypertension and concurrent lifestyle modification.
Prof. Kjeldsen, University of Oslo, Norway, on the inplementation of clinical trial results in hypertension into daily practice.
Dr. Peter Meredith, Glasgow, UK, discusses structural differences between different ARB's used in the management of blood pressure.
**Managing hypertension to protect the diabetic patient: When and how to intervene? **Prof. Tom MacDonald University of Dundee, United Kingdom